These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 17012871

  • 1. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA, Langley JM, Hesley TM, Zappacosta PS, Radley D, Smith B, Hoffenbach A, Boslego J, Silber JL.
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.
    Vaccine; 2009 Apr 28; 27(19):2540-7. PubMed ID: 19124057
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
    Diaz-Mitoma F, Halperin SA, Tapiero B, Hoffenbach A, Zappacosta PS, Radley D, Bradshaw S, Martin JC, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.
    Vaccine; 2011 Feb 01; 29(6):1324-31. PubMed ID: 21134456
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 03; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA.
    Vaccine; 2003 Sep 08; 21(25-26):3593-600. PubMed ID: 12922087
    [Abstract] [Full Text] [Related]

  • 7. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM.
    Pediatr Infect Dis J; 1998 Apr 08; 17(4):294-304. PubMed ID: 9576383
    [Abstract] [Full Text] [Related]

  • 8. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2012 Jan 08; 31(1):e24-30. PubMed ID: 22157567
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov 08; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 08; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2019 Aug 08; 15(4):809-821. PubMed ID: 30444673
    [Abstract] [Full Text] [Related]

  • 12. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D.
    Hum Vaccin; 2010 Aug 08; 6(8):640-51. PubMed ID: 20697200
    [Abstract] [Full Text] [Related]

  • 13. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule.
    Martinón-Torres F, Salamanca de la Cueva I, Horn M, Westerholt S, Bosis S, Meyer N, Cheuvart B, Virk N, Jakes RW, Duchenne M, Van den Steen P.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2342630. PubMed ID: 38687024
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2009 Mar 31; 40(2):282-94. PubMed ID: 19323013
    [Abstract] [Full Text] [Related]

  • 15. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D.
    Pediatr Infect Dis J; 2013 May 31; 32(5):521-9. PubMed ID: 23190785
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A.
    Southeast Asian J Trop Med Public Health; 2004 Sep 31; 35(3):685-92. PubMed ID: 15689088
    [Abstract] [Full Text] [Related]

  • 17. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
    Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2012 May 31; 43(3):687-98. PubMed ID: 23077849
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants.
    Tregnaghi MW, Zambrano B, Santos-Lima E.
    Pediatr Infect Dis J; 2011 Jun 31; 30(6):e88-96. PubMed ID: 21372751
    [Abstract] [Full Text] [Related]

  • 19. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, Gómez IP, Liese J, Knuf M.
    Vaccine; 2018 Feb 08; 36(7):986-996. PubMed ID: 29336924
    [Abstract] [Full Text] [Related]

  • 20. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY, Wang YH, Chang LY, Huang YC, Kao HT, Lin PY, Lu HK, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Mar 08; 11(2):129-36. PubMed ID: 16762579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.